3.4.21.B12: prostase
This is an abbreviated version!
For detailed information about prostase, go to the full flat file.
Word Map on EC 3.4.21.B12
-
3.4.21.B12
-
klk4
-
kallikreins
-
amelogenins
-
amelogenesis
-
ameloblastin
-
enamelysin
-
incisor
-
imperfecta
-
maturation-stage
-
amelx
-
amelotin
-
medicine
-
secretory-stage
-
hypomineralized
-
masp-1
-
hypomaturation
-
crystallite
-
metalloproteinase-20
-
analysis
-
diagnostics
- 3.4.21.B12
- klk4
- kallikreins
- amelogenins
-
amelogenesis
- ameloblastin
- enamelysin
- incisor
- imperfecta
-
maturation-stage
-
amelx
-
amelotin
- medicine
-
secretory-stage
-
hypomineralized
- masp-1
-
hypomaturation
-
crystallite
-
metalloproteinase-20
- analysis
- diagnostics
Reaction
proteolysis of polypeptides =
Synonyms
EM serine proteinase 1, EMSP1, enamel matrix serine protease 1, HK4, K4, kallikrein 1-related peptidase 4, kallikrein 4, kallikrein-4, kallikrein-4 proteinase, kallikrein-like protein 1, kallikrein-related peptidase, kallikrein-related peptidase 4, kallikrein-related peptidase-4, KLK, KLK-4 proteinase, KLK-L1, KLK4, More, peptidase S01.251, prostase, prostate cancer serine protease, PRSS17, S01.251, serine protease 1, serine protease 17, tissue kallikrein-related peptidase 4
ECTree
Advanced search results
Application
Application on EC 3.4.21.B12 - prostase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
analysis
-
enzyme-specific sandwich-type immunoassay using a monoclonal antibody, detection limit is 0.02 microgram per liter, and less than 0.1% cross-reactivity with other human kallikreins
diagnostics
medicine
four-kallikrein panel is a prostate screening test. An important proportion number of men presenting for biopsy falls outside the diagnostic grey zone, having a positive digital rectal exam or prostate-specific antigen 10-25 ng/ml. The four kallikrein panel has good discrimination in these men, and use of the panel reduces biopsy rates in this group of men by over 20%. The use of the panel in men with positive digital rectal exam or prostate-specific antigen 10-25 is justified
medicine
-
naturally occuring gene mutation G214A results in a truncated enzyme that lacks residue S207 of the catalytic triad. Mutation affects tooth enamel formation causing the enamel crystallites to grow incompletely in thickness or width but to normal length, i.e. autosomal recessive hypomaturation amelogenesis imperfecta
medicine
-
no significant differences in enzyme protein content between healthy prostate tissue and malignant or benign prostate
medicine
-
patients with epithelial ovarian carcinoma, carcinoma cells expressed enzyme in 80% of effusions and 82% of solid tumors, levels are highest in effusions. Enzyme expression does not predict survival
medicine
-
expression of the various tissue kallikreins like KLK4 in the endometrium and conceptus during the estrous cycle and early pregnancy in the pig can serve in the activation of growth factors and tissue remodeling during the establishment of pregnancy
medicine
-
K4 is not only expressed in prostate cancer cells, but also osteoblasts, in bone metastases. Thus, K4 may have proteolytic roles as a potential mediator of cellular interactions between prostate cancer and bone cells. Complex interactions may occur between prostate cancer and bone cells in the metastatic environment. Co-culture models are a crucial tool in evaluating cellular interactions
medicine
-
KLK-4 proteinase is essential for the final crystallite growth of enamel but is not critical for crystallite orientation, prism formation or enamel thickness
medicine
-
KLK4 initiates Ca2+ mobilization via PAR-1 and PAR-2 but not via PAR-4. KLK4 has greater efficacy for initiating Ca2+ signalling via PAR-2 than PAR-1. Signals induced by KLK4 via PARs may be important in prostate cancer
medicine
-
KLK4 is a proliferative factor with effects on cell cycle-related gene expression. It may have an important role in prostate cancer development and progression
medicine
-
tumor-associated overexpression of tissue kallikreins contributes to ovarian cancer progression. OV-MZ-6 ovarian cancer cells simultaneously expressing K4-7 display similar proliferative capacity as the vector-transfected control cells, but show significantly increased invasive behavior. Simultaneous expression of K4-7 in OV-MZ-6 cells and inoculated into the peritoneum of nude mice, results in a remarkable 92% mean increase in tumor burden compared to control cell line
medicine
-
kallikrein 4 quantification serves as an independent biomarker for the discrimination between the malignant and the benign nature of prostate tumors
medicine
KLK4 can serve as a potential therapeutic target in patients with oral cancer. Inhibition of KLK4 expression results in diminished invasive potential in OSCC cell lines